[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"biomarkers-of-aging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:biomarkers-of-aging":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100648206","phase-1-psilocybin-effects-on-healthy-aging-biomarkers-and-purpose-in-life-100648206",false,"NCT07719088","Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life","An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in Life","LONG-LIFE","Inclusion Criteria:\n\n* English speaking and able to provide informed consent and complete study procedures\n* Medically healthy, as determined by the screening physician, with no significant medical conditions that would interfere with participation or affect the safety of the subject.\n\nExclusion Criteria:\n\n* History or presence of any psychiatric or medical condition that, in the opinion of the investigator, could pose a safety risk, interfere with participation, or confound study results.\n* Abnormal ECG at screening that may increase risk during participation (e.g., prolonged QTc, arrhythmias, or other clinically significant findings as determined by the study physician).\n* Unwilling or unable to discontinue medications that may interfere with study participation, as determined by the investigator.",true,"ALL","60 Years","80 Years",{"count":22,"type":23},50,"ESTIMATED","INTERVENTIONAL",[26],"PHASE1","The LONG-LIFE study is a randomized Phase I, dose-ranging trial designed to evaluate whether psilocybin impacts aging-related biomarkers, cognitive function, and purpose\u002Fmeaning in life in medically stable older adults.\n\nUp to 50 participants will be enrolled aged 60-80 who will be randomized with equal allocation to one of four intervention groups: (1) receipt of one 25 mg dose of psilocybin; (2) receipt of two 25 mg doses of psilocybin separated by four weeks; (3) receipt of three 25 mg doses, with each dose separated by four weeks; or (4) wait-list comparator condition that does not receive psilocybin. Biomarkers of aging, cognitive performance, and behavioral measures will be assessed at baseline and longitudinally over a 12-month follow-up period. The primary endpoint occurs at the Week 16 visit. Participants randomized to the wait-list condition will be offered a single 25 mg dose of psilocybin following conclusion of the 12-month follow-up period.\n\nFindings from this Phase I study will inform dose selection for a Phase II study should results indicate a potential impact of psilocybin on relevant study endpoints.",[29,30,31],"Aging","Longevity","Biomarkers of Aging",[29,30,33,34,35,36,37],"Cognitive Function","Purpose","Meaning","Well-Being","Biomarkers","NOT_YET_RECRUITING","2026-08-13",{"date":41,"type":42},"2026-08-17","ACTUAL",{"date":44,"type":23},"2026-12",{"date":46,"type":23},"2028-12",{"name":48,"class":49},"Charles Raison","OTHER"]